SlideShare una empresa de Scribd logo
1 de 21
Descargar para leer sin conexión
The one thing I'd fix
When I was a young and idealistic doctor, I wanted to change the world. I was fascinated 
by research and by the challenge of discovering new drugs. Today, some 25 years later the 
one thing I’d like to fix is STOP CANCER!
The greatest challenge is to stop cancer cells from growing, dividing uncontrollably 
and spreading- causing great suffering. Understanding how healthy cells divide and how 
the process can go wrong - is the foundation on which efforts to beat cancer are built.
Cancer is one of the most complex 
problems in modern medicine. 
There is no one way to stop it, as it 
manifests in more than a 100 ways and 
can arise from numerous causes. 
Thousands of cancer-causing gene 
problems have already been identified, 
but there may be many more yet to be 
discovered. 
Cancer results from an accumulation of 
mistakes or abnormalities in genes that 
normally control cell survival, growth 
and migration. The resulting mass of 
new cells forms the primary tumour. 
Tumour cells can then spread (or 
metastasize) from the primary to other 
parts of the body.
Why do cells proliferate too much? 
Genes are the instruction manual for our cells, mutations are like errors in the base 
sequence. When these instructions are altered cells may begin to multiply 
uncontrollably.
What can cause gene mutations? 
Environmental factors may also be a factor in causing gene mutations. Some chemicals 
in tobacco smoke, viruses or bacteria, some chemicals or radiation. They disrupt the 
growth signalling pathway.
How can we reduce the risk of cancer? 
Stop smoking! Eat lots of fruits and vegetables. Protect yourself from too much sunlight. 
Don’t drink a lot of alcohol and smoke. Vaccines as advised by the doctor.
High Failure Rate 
The number of new drugs making the journey all the way to market is reducing. In Phase II 
clinical trials, typically around 70% of new molecules fail to progress further and a 
remarkable 50% more fail at Phase III.
Learning more and more about genes and cancer. 
The frame of reference for the field is continually changing. Each gene participates not in 
one pathway, but in many – possibly dozens. A disease may have many different 
pathways that take a wrong turn-A tangled knot rather than a straight road.
Turmoil and transition in Drug Development. Unprecedented challenges. 
*Time for products from competitors is falling. 
*Generic alternatives to existing drugs are commanding a growing share 
*Costs are rising but less than one drug in ten recovers this cost. 
*Drug development is very risky as the failure rate is high. 
*Knowledge is growing exponentially. 
*The regulatory bar is rising higher and higher. 
*Oncology’s overall success rate is so low 6.7%relative to other 
therapeutic areas 12%. Many fail in Phase III
So what is the answer? We still need to find a cure for cancer! 
 innovative collaborations will be the new model 
 Multidisciplinary and multi-sector collaborations, 
 pathway to patient benefit will be a collective effort 
Reaching out from national boundaries into a new approach of emerging collaborative 
global networks for drug discovery and development
Profit Together 
No pharmaceutical company will be able to “profit alone”. It will, rather, have to “profit 
together” by joining forces with a wide range of organisations, from academic 
institutions, hospitals and technology providers to companies new technologies to look 
deeper. 
Bill Gates urges Stanford grads to focus on progress, not profit alone
The dinosaur becomes obsolete and is replaced by a fast nimble cheetah. 
The model of Big companies 
retaining all the knowledge 
within has become obsolete. 
Managing partnerships in 
parts of the drug 
development cycle while 
retaining core assets and 
knowledge will be the 
challenge. 
Good communication skills 
will be needed as the 
industry moves from 
internal to external focus. 
Companies need to be 
nimble and quick . 
.
Building an asset light- drug development company. 
It started with outsourcing to contract research organisations but has now 
gone much further into a virtual world. Making smaller super specialized 
teams that work across international borders. The best people in the field 
are chosen to become members of the team. Outside expertise can be 
brought in whenever needed.
Changing the game. 
Being Patient centric-work 
closer with patients- making them the focus. Collaborating with doctors even before 
the search for new drug and integrating them early Scientists need to have collaborative 
ability. 
Changing the mind-set on intellectual property rights 
An enabling Intellectual Property framework has become one of the prerequisites for 
global prosperity. 
Continuing engagement with the public and government policymakers to better 
understand the challenges which drug discovery faces globally.
The one thing I'd fix
India Advantage 
India can make drugs for the 6 billion people in the world who cannot 
afford Western prices. India pharmaceuticals can reduce the burden of 
disease not just in India but globally. The Biotechnology and life science 
sector can follow the IT sector and India can become the center of 
innovation and be the drug maker for the whole world. India can make 
drugs for a tenth of the cost in the West. 
(India’s successful Mars Mission was a tenth of the cost compared to 
Western countries.)
The Early Cancer Detection is Key 
0.13 mm3 
= 500-3,000 cells 
10 mm 
103 mm3 
= 0.5-3 billion cells 
1 mm 
13 mm3 
= 0.5-3 million cells 
Courtesy by Dr. Gambhir, Stanford University
Using new technology – Molecular Imaging to Stop Cancer 
• detecting relevant disease at the earliest possible stage 
and methods to predict and monitor therapies 
• Molecular imaging using suitable probes is able to 
localize site(s) and characterize tumor status at an 
earlier stage 
• Future cancer patient management will have 
implemented Molecular Imaging for: 
– Improved tumor detection and characterization 
– Better understanding of tumor heterogeneity / 
biology 
– Tailored pathway-based therapies, individualized 
therapeutic combinations / schedule variations, 
optimized external beam radiotherapy 
– Early assessment of response 
An example- from Piramal Imaging. 
18F-labeled derivative of the natural 
amino acid glutamate 
Specific transport via amino acid 
exchanger system xC-Strong 
accumulation in various tumor 
types 
Rapid blood clearance, low background 
in healthy tissues 
Potentially guiding therapy decisions for 
improved outcome 
Currently in clinical development
Can this idea work? 
Here is an example -Piramal Enterprises acquired the Molecular Imaging assets of 
Bayer in 2012. A small team of highly committed scientists working across 
international borders was formed to complete the trials and shepherd the science 
towards regulatory approval. FDA Approves Piramal Imaging’s NeuraceqTM 
(florbetaben F18 injection) for PET Imaging of Beta-Amyloid Neuritic Plaques in 
the Brain. The group is trying to replicate the success with cancer diagnosis.
Credits 
DRG- Decision Resources Group USA Oncology Team 
Merron, Andrew AMerron@dresourcesgroup.com 
Piramal Imaging Germany 
Dr Ludger Dinkelborg ludger.dinkelborg@piramal.com 
Dr Andrew Stephens andrew.stephens@piramal.com 
-Molecular Imaging Society of India. 
Graphics- Anju Tikekar

Más contenido relacionado

La actualidad más candente

MT115 Precision Medicine: Integrating genomics to enable better patient outcomes
MT115 Precision Medicine: Integrating genomics to enable better patient outcomesMT115 Precision Medicine: Integrating genomics to enable better patient outcomes
MT115 Precision Medicine: Integrating genomics to enable better patient outcomesDell EMC World
 
Oncology Clinical Development Challenges and Opportunities in the Phase 1 Set...
Oncology Clinical Development Challenges and Opportunities in the Phase 1 Set...Oncology Clinical Development Challenges and Opportunities in the Phase 1 Set...
Oncology Clinical Development Challenges and Opportunities in the Phase 1 Set...Roberto Lara
 
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Andrew Aijian
 
Advances in Personalized Medicine and Improving the Quality of Life: The Futu...
Advances in Personalized Medicine and Improving the Quality of Life: The Futu...Advances in Personalized Medicine and Improving the Quality of Life: The Futu...
Advances in Personalized Medicine and Improving the Quality of Life: The Futu...Cancer Treatment Centers of America
 
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...Medpace
 
How Advanced Therapies are Changing the Landscape of Rare Disease
How Advanced Therapies are Changing the Landscape of Rare DiseaseHow Advanced Therapies are Changing the Landscape of Rare Disease
How Advanced Therapies are Changing the Landscape of Rare DiseaseMedpace
 
Precision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsPrecision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsWarren Kibbe
 
Oncology Big Data: A Mirage or Oasis of Clinical Value?
Oncology Big Data:  A Mirage or Oasis of Clinical Value? Oncology Big Data:  A Mirage or Oasis of Clinical Value?
Oncology Big Data: A Mirage or Oasis of Clinical Value? Michael Peters
 
14 technologies that will shape the future of cancer care
14 technologies that will shape the future of cancer care14 technologies that will shape the future of cancer care
14 technologies that will shape the future of cancer careMpower Medical Inc
 
Clinical Genomics and Medicine
Clinical Genomics and MedicineClinical Genomics and Medicine
Clinical Genomics and MedicineWarren Kibbe
 
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
 
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Andrew Aijian
 
The Business of Genomic Testing by James Crawford
The Business of Genomic Testing by James CrawfordThe Business of Genomic Testing by James Crawford
The Business of Genomic Testing by James CrawfordKnome_Inc
 
Dr Colin Gaynor - Project managers as truth seekers - it's in our DNA
Dr Colin Gaynor - Project managers as truth seekers - it's in our DNADr Colin Gaynor - Project managers as truth seekers - it's in our DNA
Dr Colin Gaynor - Project managers as truth seekers - it's in our DNAAssociation for Project Management
 
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...Andrew Aijian
 
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Andrew Aijian
 
Certis oncologist slideshare 7.28.18
Certis oncologist slideshare 7.28.18Certis oncologist slideshare 7.28.18
Certis oncologist slideshare 7.28.18ArthurHolmes2
 

La actualidad más candente (20)

Pharmacogenomic presentation medication saftey 110417 final2
Pharmacogenomic presentation  medication saftey 110417 final2Pharmacogenomic presentation  medication saftey 110417 final2
Pharmacogenomic presentation medication saftey 110417 final2
 
MT115 Precision Medicine: Integrating genomics to enable better patient outcomes
MT115 Precision Medicine: Integrating genomics to enable better patient outcomesMT115 Precision Medicine: Integrating genomics to enable better patient outcomes
MT115 Precision Medicine: Integrating genomics to enable better patient outcomes
 
Oncology Clinical Development Challenges and Opportunities in the Phase 1 Set...
Oncology Clinical Development Challenges and Opportunities in the Phase 1 Set...Oncology Clinical Development Challenges and Opportunities in the Phase 1 Set...
Oncology Clinical Development Challenges and Opportunities in the Phase 1 Set...
 
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...
 
Advances in Personalized Medicine and Improving the Quality of Life: The Futu...
Advances in Personalized Medicine and Improving the Quality of Life: The Futu...Advances in Personalized Medicine and Improving the Quality of Life: The Futu...
Advances in Personalized Medicine and Improving the Quality of Life: The Futu...
 
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
Challenges and Considerations in Designing and Conducting Immuno-Oncology Cli...
 
How Advanced Therapies are Changing the Landscape of Rare Disease
How Advanced Therapies are Changing the Landscape of Rare DiseaseHow Advanced Therapies are Changing the Landscape of Rare Disease
How Advanced Therapies are Changing the Landscape of Rare Disease
 
Precision Medicine in Oncology Informatics
Precision Medicine in Oncology InformaticsPrecision Medicine in Oncology Informatics
Precision Medicine in Oncology Informatics
 
VAR
VARVAR
VAR
 
Theralase Photodynamic Compounds Destroy Cancer
Theralase Photodynamic Compounds Destroy CancerTheralase Photodynamic Compounds Destroy Cancer
Theralase Photodynamic Compounds Destroy Cancer
 
Oncology Big Data: A Mirage or Oasis of Clinical Value?
Oncology Big Data:  A Mirage or Oasis of Clinical Value? Oncology Big Data:  A Mirage or Oasis of Clinical Value?
Oncology Big Data: A Mirage or Oasis of Clinical Value?
 
14 technologies that will shape the future of cancer care
14 technologies that will shape the future of cancer care14 technologies that will shape the future of cancer care
14 technologies that will shape the future of cancer care
 
Clinical Genomics and Medicine
Clinical Genomics and MedicineClinical Genomics and Medicine
Clinical Genomics and Medicine
 
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...
 
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...
 
The Business of Genomic Testing by James Crawford
The Business of Genomic Testing by James CrawfordThe Business of Genomic Testing by James Crawford
The Business of Genomic Testing by James Crawford
 
Dr Colin Gaynor - Project managers as truth seekers - it's in our DNA
Dr Colin Gaynor - Project managers as truth seekers - it's in our DNADr Colin Gaynor - Project managers as truth seekers - it's in our DNA
Dr Colin Gaynor - Project managers as truth seekers - it's in our DNA
 
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...
 
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
Update on the Adoption and Utilization of Emerging Precision Medicine Biomark...
 
Certis oncologist slideshare 7.28.18
Certis oncologist slideshare 7.28.18Certis oncologist slideshare 7.28.18
Certis oncologist slideshare 7.28.18
 

Similar a The one thing I'd fix

Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1Sumith Kularatne
 
Developing Cell Specific Cancer Treatments
Developing Cell Specific Cancer TreatmentsDeveloping Cell Specific Cancer Treatments
Developing Cell Specific Cancer TreatmentsMichele Johnson
 
Pich Deck for Pepper Bio, for TechCruch's Pitch Deck Teardown series
Pich Deck for Pepper Bio, for TechCruch's Pitch Deck Teardown seriesPich Deck for Pepper Bio, for TechCruch's Pitch Deck Teardown series
Pich Deck for Pepper Bio, for TechCruch's Pitch Deck Teardown seriesHajeJanKamps
 
Personalized Cancer Care
Personalized Cancer CarePersonalized Cancer Care
Personalized Cancer CarePaige W
 
Get the right cancer drug, at right Time
Get the right cancer drug, at right TimeGet the right cancer drug, at right Time
Get the right cancer drug, at right TimeSubin Suresh
 
Target Therapy For Ovarian Cancer
Target Therapy For Ovarian CancerTarget Therapy For Ovarian Cancer
Target Therapy For Ovarian CancerDebbie Beason
 
Animal Models And Clinical Trials
Animal Models And Clinical TrialsAnimal Models And Clinical Trials
Animal Models And Clinical TrialsAmanda Barber
 
The Treatment Of Cancer And Cancer
The Treatment Of Cancer And CancerThe Treatment Of Cancer And Cancer
The Treatment Of Cancer And CancerStephanie Barker
 
Emerging Technologies and Tools in Precision Medicine Research
Emerging Technologies and Tools in Precision Medicine ResearchEmerging Technologies and Tools in Precision Medicine Research
Emerging Technologies and Tools in Precision Medicine ResearchClinosolIndia
 
The 10 Most Impactful Leaders in Life Science.pdf
The 10 Most Impactful Leaders in Life Science.pdfThe 10 Most Impactful Leaders in Life Science.pdf
The 10 Most Impactful Leaders in Life Science.pdfTHECIOWORLD
 
Towards Personalized Medicine
Towards Personalized MedicineTowards Personalized Medicine
Towards Personalized MedicineMichel Dumontier
 
Childhood Cancer Research Paper
Childhood Cancer Research PaperChildhood Cancer Research Paper
Childhood Cancer Research PaperJennifer Jones
 
Adenomatous Polyps Theory
Adenomatous Polyps TheoryAdenomatous Polyps Theory
Adenomatous Polyps TheoryLana Sorrels
 
Cmt newsletter-spring-2015
Cmt newsletter-spring-2015Cmt newsletter-spring-2015
Cmt newsletter-spring-2015Sean Ekins
 
Analytical method development of anticancer drugs by UV visible spectroscopy
Analytical method development of anticancer drugs by UV visible spectroscopyAnalytical method development of anticancer drugs by UV visible spectroscopy
Analytical method development of anticancer drugs by UV visible spectroscopySudip Khan
 
The 10 most innovative companies in gene therapy
The 10 most innovative companies in gene therapyThe 10 most innovative companies in gene therapy
The 10 most innovative companies in gene therapyinsightscare
 
HealthPanel Concept pitchdeck
HealthPanel Concept pitchdeckHealthPanel Concept pitchdeck
HealthPanel Concept pitchdecksmworth
 

Similar a The one thing I'd fix (20)

Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
 
Developing Cell Specific Cancer Treatments
Developing Cell Specific Cancer TreatmentsDeveloping Cell Specific Cancer Treatments
Developing Cell Specific Cancer Treatments
 
Pich Deck for Pepper Bio, for TechCruch's Pitch Deck Teardown series
Pich Deck for Pepper Bio, for TechCruch's Pitch Deck Teardown seriesPich Deck for Pepper Bio, for TechCruch's Pitch Deck Teardown series
Pich Deck for Pepper Bio, for TechCruch's Pitch Deck Teardown series
 
Webinar: Turning Molecules into Medicines
Webinar: Turning Molecules into MedicinesWebinar: Turning Molecules into Medicines
Webinar: Turning Molecules into Medicines
 
Personalized Cancer Care
Personalized Cancer CarePersonalized Cancer Care
Personalized Cancer Care
 
Get the right cancer drug, at right Time
Get the right cancer drug, at right TimeGet the right cancer drug, at right Time
Get the right cancer drug, at right Time
 
Target Therapy For Ovarian Cancer
Target Therapy For Ovarian CancerTarget Therapy For Ovarian Cancer
Target Therapy For Ovarian Cancer
 
Animal Models And Clinical Trials
Animal Models And Clinical TrialsAnimal Models And Clinical Trials
Animal Models And Clinical Trials
 
The Treatment Of Cancer And Cancer
The Treatment Of Cancer And CancerThe Treatment Of Cancer And Cancer
The Treatment Of Cancer And Cancer
 
Emerging Technologies and Tools in Precision Medicine Research
Emerging Technologies and Tools in Precision Medicine ResearchEmerging Technologies and Tools in Precision Medicine Research
Emerging Technologies and Tools in Precision Medicine Research
 
Campbell stewardship report 2011
Campbell stewardship report 2011Campbell stewardship report 2011
Campbell stewardship report 2011
 
The 10 Most Impactful Leaders in Life Science.pdf
The 10 Most Impactful Leaders in Life Science.pdfThe 10 Most Impactful Leaders in Life Science.pdf
The 10 Most Impactful Leaders in Life Science.pdf
 
Towards Personalized Medicine
Towards Personalized MedicineTowards Personalized Medicine
Towards Personalized Medicine
 
Childhood Cancer Research Paper
Childhood Cancer Research PaperChildhood Cancer Research Paper
Childhood Cancer Research Paper
 
Adenomatous Polyps Theory
Adenomatous Polyps TheoryAdenomatous Polyps Theory
Adenomatous Polyps Theory
 
Cmt newsletter-spring-2015
Cmt newsletter-spring-2015Cmt newsletter-spring-2015
Cmt newsletter-spring-2015
 
Analytical method development of anticancer drugs by UV visible spectroscopy
Analytical method development of anticancer drugs by UV visible spectroscopyAnalytical method development of anticancer drugs by UV visible spectroscopy
Analytical method development of anticancer drugs by UV visible spectroscopy
 
The 10 most innovative companies in gene therapy
The 10 most innovative companies in gene therapyThe 10 most innovative companies in gene therapy
The 10 most innovative companies in gene therapy
 
HealthPanel Concept pitchdeck
HealthPanel Concept pitchdeckHealthPanel Concept pitchdeck
HealthPanel Concept pitchdeck
 
21. Maurice Mayrides - Esperantra
21. Maurice Mayrides -  Esperantra21. Maurice Mayrides -  Esperantra
21. Maurice Mayrides - Esperantra
 

Más de Swati Piramal

Mobile Health Services-a breakthrough model for serving rural populations
Mobile Health Services-a breakthrough model for serving rural populationsMobile Health Services-a breakthrough model for serving rural populations
Mobile Health Services-a breakthrough model for serving rural populationsSwati Piramal
 
Forbes India - Jan 2015
Forbes India - Jan 2015Forbes India - Jan 2015
Forbes India - Jan 2015Swati Piramal
 
My plan B creating a paradise on earth
My plan B creating a paradise on earthMy plan B creating a paradise on earth
My plan B creating a paradise on earthSwati Piramal
 

Más de Swati Piramal (6)

A far afternoon
A far afternoonA far afternoon
A far afternoon
 
Mobile Health Services-a breakthrough model for serving rural populations
Mobile Health Services-a breakthrough model for serving rural populationsMobile Health Services-a breakthrough model for serving rural populations
Mobile Health Services-a breakthrough model for serving rural populations
 
Forbes India - Jan 2015
Forbes India - Jan 2015Forbes India - Jan 2015
Forbes India - Jan 2015
 
Big ideas 2015
Big ideas 2015Big ideas 2015
Big ideas 2015
 
My plan B creating a paradise on earth
My plan B creating a paradise on earthMy plan B creating a paradise on earth
My plan B creating a paradise on earth
 
How i do things
How i do thingsHow i do things
How i do things
 

Último

How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 

Último (20)

How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 

The one thing I'd fix

  • 2. When I was a young and idealistic doctor, I wanted to change the world. I was fascinated by research and by the challenge of discovering new drugs. Today, some 25 years later the one thing I’d like to fix is STOP CANCER!
  • 3. The greatest challenge is to stop cancer cells from growing, dividing uncontrollably and spreading- causing great suffering. Understanding how healthy cells divide and how the process can go wrong - is the foundation on which efforts to beat cancer are built.
  • 4. Cancer is one of the most complex problems in modern medicine. There is no one way to stop it, as it manifests in more than a 100 ways and can arise from numerous causes. Thousands of cancer-causing gene problems have already been identified, but there may be many more yet to be discovered. Cancer results from an accumulation of mistakes or abnormalities in genes that normally control cell survival, growth and migration. The resulting mass of new cells forms the primary tumour. Tumour cells can then spread (or metastasize) from the primary to other parts of the body.
  • 5. Why do cells proliferate too much? Genes are the instruction manual for our cells, mutations are like errors in the base sequence. When these instructions are altered cells may begin to multiply uncontrollably.
  • 6. What can cause gene mutations? Environmental factors may also be a factor in causing gene mutations. Some chemicals in tobacco smoke, viruses or bacteria, some chemicals or radiation. They disrupt the growth signalling pathway.
  • 7. How can we reduce the risk of cancer? Stop smoking! Eat lots of fruits and vegetables. Protect yourself from too much sunlight. Don’t drink a lot of alcohol and smoke. Vaccines as advised by the doctor.
  • 8. High Failure Rate The number of new drugs making the journey all the way to market is reducing. In Phase II clinical trials, typically around 70% of new molecules fail to progress further and a remarkable 50% more fail at Phase III.
  • 9. Learning more and more about genes and cancer. The frame of reference for the field is continually changing. Each gene participates not in one pathway, but in many – possibly dozens. A disease may have many different pathways that take a wrong turn-A tangled knot rather than a straight road.
  • 10. Turmoil and transition in Drug Development. Unprecedented challenges. *Time for products from competitors is falling. *Generic alternatives to existing drugs are commanding a growing share *Costs are rising but less than one drug in ten recovers this cost. *Drug development is very risky as the failure rate is high. *Knowledge is growing exponentially. *The regulatory bar is rising higher and higher. *Oncology’s overall success rate is so low 6.7%relative to other therapeutic areas 12%. Many fail in Phase III
  • 11. So what is the answer? We still need to find a cure for cancer!  innovative collaborations will be the new model  Multidisciplinary and multi-sector collaborations,  pathway to patient benefit will be a collective effort Reaching out from national boundaries into a new approach of emerging collaborative global networks for drug discovery and development
  • 12. Profit Together No pharmaceutical company will be able to “profit alone”. It will, rather, have to “profit together” by joining forces with a wide range of organisations, from academic institutions, hospitals and technology providers to companies new technologies to look deeper. Bill Gates urges Stanford grads to focus on progress, not profit alone
  • 13. The dinosaur becomes obsolete and is replaced by a fast nimble cheetah. The model of Big companies retaining all the knowledge within has become obsolete. Managing partnerships in parts of the drug development cycle while retaining core assets and knowledge will be the challenge. Good communication skills will be needed as the industry moves from internal to external focus. Companies need to be nimble and quick . .
  • 14. Building an asset light- drug development company. It started with outsourcing to contract research organisations but has now gone much further into a virtual world. Making smaller super specialized teams that work across international borders. The best people in the field are chosen to become members of the team. Outside expertise can be brought in whenever needed.
  • 15. Changing the game. Being Patient centric-work closer with patients- making them the focus. Collaborating with doctors even before the search for new drug and integrating them early Scientists need to have collaborative ability. Changing the mind-set on intellectual property rights An enabling Intellectual Property framework has become one of the prerequisites for global prosperity. Continuing engagement with the public and government policymakers to better understand the challenges which drug discovery faces globally.
  • 17. India Advantage India can make drugs for the 6 billion people in the world who cannot afford Western prices. India pharmaceuticals can reduce the burden of disease not just in India but globally. The Biotechnology and life science sector can follow the IT sector and India can become the center of innovation and be the drug maker for the whole world. India can make drugs for a tenth of the cost in the West. (India’s successful Mars Mission was a tenth of the cost compared to Western countries.)
  • 18. The Early Cancer Detection is Key 0.13 mm3 = 500-3,000 cells 10 mm 103 mm3 = 0.5-3 billion cells 1 mm 13 mm3 = 0.5-3 million cells Courtesy by Dr. Gambhir, Stanford University
  • 19. Using new technology – Molecular Imaging to Stop Cancer • detecting relevant disease at the earliest possible stage and methods to predict and monitor therapies • Molecular imaging using suitable probes is able to localize site(s) and characterize tumor status at an earlier stage • Future cancer patient management will have implemented Molecular Imaging for: – Improved tumor detection and characterization – Better understanding of tumor heterogeneity / biology – Tailored pathway-based therapies, individualized therapeutic combinations / schedule variations, optimized external beam radiotherapy – Early assessment of response An example- from Piramal Imaging. 18F-labeled derivative of the natural amino acid glutamate Specific transport via amino acid exchanger system xC-Strong accumulation in various tumor types Rapid blood clearance, low background in healthy tissues Potentially guiding therapy decisions for improved outcome Currently in clinical development
  • 20. Can this idea work? Here is an example -Piramal Enterprises acquired the Molecular Imaging assets of Bayer in 2012. A small team of highly committed scientists working across international borders was formed to complete the trials and shepherd the science towards regulatory approval. FDA Approves Piramal Imaging’s NeuraceqTM (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Neuritic Plaques in the Brain. The group is trying to replicate the success with cancer diagnosis.
  • 21. Credits DRG- Decision Resources Group USA Oncology Team Merron, Andrew AMerron@dresourcesgroup.com Piramal Imaging Germany Dr Ludger Dinkelborg ludger.dinkelborg@piramal.com Dr Andrew Stephens andrew.stephens@piramal.com -Molecular Imaging Society of India. Graphics- Anju Tikekar